I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Polycystic ovary syndrome (PCOS) is one of the most common endocrine and metabolic disorders with a prevalence of approximately 60--70% in Chinese obese women of reproductive age.\[[@ref1]\] The common manifestations of PCOS are oligomenorrhea, chronic anovulation, hyperandrogenism, hyperinsulinemia, and polycystic ovaries on ovarian ultrasonography.\[[@ref2]\] PCOS increases the risks of type 2 diabetes, cardiovascular disease, endometrial cancer, and ovarian cancer.\[[@ref3][@ref4]\] The pathogenesis of PCOS remains unclear, although it is considered to be the result of interaction between genetic, environmental, and lifestyle factors. Although the 2003 Rotterdam criteria provide the most widely used diagnostic standard, the diagnosis of PCOS is difficult because its symptoms are heterogeneous.

Metabolomics is a powerful tool for identifying useful biomarkers in the diagnosis of PCOS and for studying its pathogenesis. Metabolomic studies of PCOS plasma samples have been performed using hydrogen-1 nuclear magnetic resonance,\[[@ref5][@ref6]\] gas chromatography-mass spectrometry (GC-MS),\[[@ref7]\] and liquid chromatography-mass spectrometry (LC-MS).\[[@ref8]\] Multiple metabolic disorders have been observed in PCOS, including the metabolism of steroid hormones, carbohydrates, amino acid, and lipids. Branched-chain amino acids, creatinine, and lipids have been reported as potential biomarkers. However, blood specimen collection is invasive and inconvenient. There have been few metabolomic studies of PCOS urinary samples, and in those that were carried out, the metabolic profile of the PCOS patients' urine was not clear.

In this study, a metabolomic approach based on GC-MS was used to investigate the metabolic profiles of PCOS patients through analysis of urine samples to identify useful biomarkers for the diagnosis of PCOS.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Ethical approval {#sec2-1}
----------------

Ethics committee approval was obtained for this study from the Maternal and Child Health Hospital of Hunan Province, and written informed consent was obtained from all participants.

Participants {#sec2-2}
------------

The study individuals consisted of 21 patients with PCOS and 16 healthy women as controls. The patients' PCOS diagnoses were based on the 2003 Rotterdam criteria.\[[@ref9]\] Each patient met at least two of the following criteria: (1) oligomenorrhea and/or chronic anovulation; (2) clinical and/or biochemical hyperandrogenism; and (3) polycystic ovary morphology on ultrasound scan following the exclusion of Cushing\'s syndrome, congenital adrenal hyperplasia, androgen-secreting tumor, and other related disorders. The controls were female members of the staff who volunteered to participate. The specific inclusion criteria for the healthy controls included the following: regular 21--35-day menstrual cycles, no evidence of polycystic ovaries, and no evidence of hyperandrogenism. The exclusion criteria for both groups were the presence of thyroid disease, hematological disease, cardiovascular disease, liver disease, and the use of hormonal medications within the previous three months.

Urine samples for all individuals were collected in untreated vials, mainly in the morning before breakfast during the follicular phase of the menstrual cycle, or amenorrhea. Each urine sample was aliquoted into 1.5 ml Eppendorf tubes and frozen at −80°C immediately after collection until analysis. Serum follicle-stimulating hormone and luteinizing hormone (LH), as well as total testosterone (T), estradiol (E2), and prolactin (PRL) levels, were analyzed using an automated chemiluminescence system.

Gas chromatography-mass spectrometry analysis {#sec2-3}
---------------------------------------------

The urinary aliquots (100 μl) were thawed at room temperature. To facilitate the removal of interfering urea, the urine samples were first supplemented with 30.0 μl urease (1.2 U/μl) at 37°C for 30 min. Each sample was then spiked with heptadecanoic acid (0.5 mg/ml, 50 μl). The proteins were then precipitated by the addition of 800 μl ethanol and removed after 15 min of centrifugation (3000 *×g*). The deproteinized solutions were subsequently supplemented with 40 μl of hydroxylamine hydrochloride (0.04 mol/L) and 60 μl Ba (OH)~2~ (0.05 mol/L). Then, the solution mixtures were incubated at room temperature for 20 minutes. Once evaporated to dryness, the samples were converted to trimethylsilyl (TMS) derivatives with 100 μl of BSTFA/TMCS (100:1) and were analyzed using an Agilent GC-MS system (7890-5975C; Agilent Technologies, Palo Alto, CA, USA). Following injections in the gas chromatograph system at a split ratio of 50:1, samples were separated using a fused silica HP-5 capillary column. The column temperature was initially set at 60°C for 4 min, then, increased to 320°C at a rate of 6.5°C/min, and finally, maintained for 10 min. The parameters of the mass spectrum were as follows: Mass spectrometry was performed over a mass range of 50--800 m/z. The mass spectrometer was operated in electron-impact (EI) mode at an ionization energy level of 70 eV. The source temperature and interphase temperature were 230°C and 300°C, respectively. We locked heptadecanoic acid at 36 min by means of retention-time locking technology (Agilent) to stabilize the retention times of each peak. The total ion chromatograms (TICs) and fragmentation patterns were acquired using the ChemStation software (Agilent, California, USA). The fragmentation pattern of each compound was compared with a standard mass chromatogram in the National Institute of Standards and Technology (NIST) mass spectra library. The ChemStation software then generated a list of similarities compared to every substance within the NIST library for each peak, and the compound was assigned a name when the peak had a similarity index of more than 70%.

Each sample was represented by a GC-MS TIC, and the ion peak areas of the compounds were integrated after GC-MS analysis. The peak-area ratio of each compound to creatinine was calculated as the response, and the results were expressed as ratios to the urinary creatinine concentration.

Statistical analysis {#sec2-4}
--------------------

The Statistical Package for the Social Sciences (SPSS, Version 20.0, Chicago, IL, USA) was used for data analysis. Data of normal distribution were presented as mean ± standard deviation (SD), and data of unnormal distribution were presented as median and interquartile range. The Student\'s *t*-test and rank sum test were applied to validate the statistical significance of the differences between the two groups. A *P* \< 0.05 was considered statistically significant. All the data from the differentially expressed compounds were used to construct PCA models by means of the Mass Profiler Professional software (Agilent, California, USA). The specificity and sensitivity of the compound were assessed using the area under the curve (AUC) of the receiver-operating characteristic (ROC) curves.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Demographic data {#sec2-5}
----------------

The demographic data of women with and without PCOS were analyzed in this study. As expected, we found no differences in terms of mean age (26.0 ± 3.9 years vs. 27.8 ± 2.4 years, *t* = −1.574, *P* = 0.13), body mass index (22.39 ± 4.60 kg/m^2^ vs. 20.64 ± 1.65 kg/m^2^, *t* = 1.618, *P* = 0.12), or waist-hip ratio (0.81 ± 0.06 vs. 0.82 ± 0.05, *t* = −0.396, *P* = 0.69) between the women in the PCOS group and those in the control group. However, when compared with the controls, the patients with PCOS presented with increased testosterone (1.61 ± 0.69 nmol/L vs. 0.81 ± 0.29 nmol/L, *t* = 4.737, *P* \< 0.001), LH (15.68 ± 9.87 U/L vs. 5.40 ± 1.29 U/L, *t* = 4.720, *P* \< 0.001), and estradiol (177.87 ± 58.45 pmol/L vs. 113.23 ± 47.04 pmol/L, *t* = 3.617, *P* = 0.001).

Gas chromatography-mass spectrometry data {#sec2-6}
-----------------------------------------

Following the normalization of the data using creatinine as an internal standard, 35 urine metabolites relevant to the disease were identified using the Student\'s t- test with *P* \< 0.05. The name, retention time, regulation, and statistical analysis of the metabolites derived from the non-targeted GC-MS analysis are summarized in\[[Table 1](#T1){ref-type="table"}\]. The 35 metabolites were divided into four categories: short-chain fatty acids, free fatty acids, amino acids, and other types that could not be classified clearly into any of the previous three categories. Only succinic acid was significantly down-expressed in the PCOS group compared with the controls, while the remaining 34 urine metabolites were up-expressed in the women with PCOS compared with the controls. A PCA model was constructed using these differentially expressed metabolite intensities as variables. The PCA scores plot shows that the different urine samples were distributed into two different regions \[[Figure 1](#F1){ref-type="fig"}\].

###### 

Urine metabolites showing statistically significant differences between PCOS patients and controls (mmol/mol creatinine)

  Metabolite                        PCOS group (*n* = 21)     Control group (*n* = 16)   *Z*      *P*
  --------------------------------- ------------------------- -------------------------- -------- ---------
  Lactose                           10.01 (0, 13.99)          2.35 (0.16, 3.26)          −2.059   0.042
  Arabic candy                      0.04 (0, 8.45)            0.01 (0, 0.81)             −2.029   0.017
  Stearic acid                      2.35 (1.47, 3.14)         0.05 (0, 0.14)             −4.577   \<0.001
  Palmitic acid                     2.13 (1.07, 2.79)         0 (0, 0)                   −4.654   \<0.001
  D-gluconic acid                   141.69 (77.54, 343.61)    60.96 (43.30, 127.73)      −3.626   0.049
  3-hydroxypropionic acid           562.25 (0, 1005.65)       169.56 (0, 374.13)         −2.809   0.007
  Benzoylglycine                    239.99 (16.17, 897.75)    10.41 (0, 32.61)           −4.407   \<0.001
  Ribosinic acid-5                  2.45 (0.27, 3.77)         0.72 (0.33, 1.21)          −2.040   0.042
  Arabinitol                        2.24 (0, 4.18)            0 (0, 0)                   −2.354   0.032
  Cis-aconitic acid-E               7.11 (0.16, 9.96)         1.17 (0.82, 2.10)          −2.594   0.016
  Fucose                            2.88 (0, 7.36)            0.32 (0, 0.59)             −2.880   0.009
  Suberic acid                      10.76 (0, 27.32)          1.24 (0, 2.15)             −2.110   0.002
  3,4,5-hydroxyvaleric acid         4.08 (0.01, 16.17)        1.66 (0.76, 2.84)          −2.468   0.019
  4-hydroxyphenylacetic acid        123.83 (80.20, 192.74)    33.60 (19.75, 59.19)       −3.757   \<0.001
  α-ketoglutarate                   605.97 (53.51, 1030.29)   61.59 (0, 136.38)          −3.314   0.001
  3-Hydroxy-3-Methylglutaric acid   2.42 (0, 6.65)            0.48 (0.08, 0.89)          −2.195   0.009
  2-hydroxyglutaric acid            5.07 (1.96, 8.37)         0.52 (0.06, 1.20 )         −3.255   0.001
  Threonic acid                     1.84 (1.31, 3.00)         0.35 (0.24, 0.56)          −3.693   \<0.001
  Inosine                           4.87 (2.25, 7.77)         0.25 (0.20, 0.48)          −3.807   \<0.001
  2,3,4-hydroxybutyric acid         9.25 (0.14, 13.83)        1.96 (1.60, 4.25)          −2.687   0.005
  5-Oxoproline                      15.39 (6.47, 61.65)       3.26 (0.51, 6.36)          −3.170   0.0001
  Erythrocytes-2                    8.34 (0,12.73)            2.06 (0, 3.94)             −2.508   0.014
  Erythrocytes-1                    3.09 (0,5.46)             0.46 (0, 1.11)             −3.140   0.002
  3,4-hydroxybutyric acid           7.47 (6.35,13.56)         0.46 (0, 1.50)             −3.914   \<0.001
  Threonine                         4.08 (1.08, 12.48)        0.02 (0, 0.26)             −4.745   \<0.001
  Serine                            5.61 (0, 15.85)           0 (0, 0)                   −4.266   \<0.001
  Uracil                            1.70 (0, 23.00)           0.62 (0, 0.93)             −2.546   0.026
  Glyceryl acid                     7.31 (4.82, 10.99)        0.83 (0.50, 1.52)          −3.693   \<0.001
  Glycine                           9.10 (5.81, 25.42)        1.23 (0.58, 2.47)          −3.693   \<0.001
  Phosphoethanolamine               22.53 (15.76, 36.04)      4.24 (2.41, 5.76)          −3.311   0.001
  4-hydroxybutyric acid             16.70 (10.82, 30.19)      3.35 (0.40, 5.17)          −3.411   \<0.001
  Oxalic acid                       1.88 (0, 2.58)            0.68 (0, 1.42)             −2.975   0.024
  Glycolic acid                     36.98 (26.98, 53.55)      6.20 (3.07, 13.43)         −3.614   \<0.001
  2-hydroxyisobutyric acid          1.33 (0, 3. 54)           0 (0,0)                    −2.354   0.032
  Succinic acid                     0 (0, 0)                  38.94 (4.16, 51.30)        −4.553   \<0.001

PCOS: Polycystic ovary syndrome.

![A PCA score plot based on differentially expressed compounds (red squares represent the control group and blue triangles represent the PCOS group). PCA: Principal component analysis; PCOS: Polycystic ovary syndrome.](CMJ-131-945-g001){#F1}

Investigation of the metabolite biomarkers {#sec2-7}
------------------------------------------

To identify useful biomarkers for the diagnosis of PCOS, the specificity and sensitivity of each differentially expressed metabolite were assessed in this study. Among these differentially expressed metabolites, four compounds, including stearic acid, palmitic acid, benzoylglycine, and threonine, were selected as potential biomarkers and are summarized in [Table 2](#T2){ref-type="table"}.

###### 

ROC analysis with AUC, specificity, and sensitivity of each PCOS potential biomarkers

  Parameters       AUC     Best cutoff value (mmol/mol creatinine)   Sensitivity   Specificity
  ---------------- ------- ----------------------------------------- ------------- -------------
  Stearic acid     0.947   1.238                                     0.850         1.000
  Palmitic acid    0.991   1.050                                     0.850         1.000
  Benzoylglycine   0.905   0.046                                     0.850         0.937
  Threonine        0.941   0.645                                     0.800         1.000

ROC: Receiver operating characteristic; AUC: Area under the curve; PCOS: Polycystic ovary syndrome.

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

PCOS is considered to be an endocrine and metabolic syndrome that increases the risk of many diseases.\[[@ref10][@ref11][@ref12][@ref13]\] The pathogenesis of PCOS remains unclear, and there is no single diagnostic marker for PCOS.\[[@ref14]\] Here, we attempted to explore the metabolic profile of the urine of the PCOS patient group through GC-MS.

The results of our study showed that there were clear differences between the metabolomic profiles of urine in the women with PCOS compared with the controls. The PCA score plot shows an obvious differentiation between the two groups. PCOS has been reported to be associated with impaired lipid metabolism, and a dramatic increase in fatty acids leads to significant lipid profile changes in PCOS patients.\[[@ref6][@ref15][@ref16][@ref17]\] Fatty acids are an important energy source in the body and provide energy through β-oxidation. Studies have shown that PCOS is related to a decreased fatty acid oxidation capacity, and as a result, excessive fatty acids accumulate in the body causing lipotoxicity. Increased circulating free fatty acids have many adverse metabolic effects, including dyslipidemia, insulin resistance, type 2 diabetes, and hypertension. In this study, we observed elevated levels of some short-chain fatty acids and free fatty acids in the urine.\[[@ref18]\] Apart from lipids, the levels of some amino acids, such as threonine, serine, and glycine, also differed between the PCOS patients and the controls. Amino acids play an important role both as basic substrates and as regulators in many metabolic pathways.\[[@ref19]\] Specifically, amino acids and their metabolic intermediates play key roles in anabolic processes and the regulation of the metabolic pathways. Further study of these metabolic pathways using larger populations is needed to understand the pathogenesis of PCOS.

The metabolites found in the urine of the women with PCOS in our study differed from the results of a recently published study on metabolomics and PCOS. The results of that study showed that 59 urine metabolites were found at different concentrations in PCOS patients, including aromatic heteropolycyclic compounds, amino acids and peptides, lipids, and other types. Significant decreases in the levels of most of the aromatic heteropolycyclic compounds and increases in the levels of benzofenap, FMNH2, and 11 metabolites classified into the amino acid and peptide category were observed in the PCOS patients compared with the controls.\[[@ref20]\] The differences in the metabolite changes found in both studies may have been the result of different approaches and differential protein binding.

PCOS is a complex disease with no uniform diagnostic criteria, making it difficult to diagnose.\[[@ref21]\] Another study identified two novel potential urinary biomarkers, testosterone-glucuronide and 11α-hydroxyprogesterone, and four candidate urinary biomarkers in PCOS patients using a metabolomic approach.\[[@ref20]\] Here, differential metabolites of PCOS were investigated to ascertain the possibility of potential biomarkers for PCOS diagnostics. The classification performance was assessed by AUC of ROC curves performed using the values of these PCOS markers. The specificity and sensitivity values demonstrate the possibility of using these markers for diagnosing PCOS. The largest AUC value (0.991) with high specificity and sensitivity was obtained by the ROC curve of palmitic acid at the cutoff value. Stearic acid, benzoylglycine, and threonine also showed high AUC values with high specificity and sensitivity. These results demonstrate that palmitic acid and three other potential biomarkers may offer good diagnostic value for the diagnosis of PCOS. However, it remains uncertain whether these biomarkers could distinguish polycystic ovary syndrome from other metabolic diseases or divide polycystic ovary syndrome into subgroups. These potential biomarker candidates also confirmed that the pathogenesis of PCOS is closely related to multiple etiologies and pathogeneses. Based on the above findings, further studies should be carried out to verify the changes and the targeted metabolites.

In conclusion, this study evaluated metabolomic profiles in the urine of women with PCOS compared with controls. We found 35 urine metabolites at different concentrations in the PCOS patients. The study revealed four potential urinary biomarkers in PCOS patients. Further research of the differently expressed metabolites is required to understand the mechanism underlying the pathogenesis of PCOS. In addition, further study of the identified biomarkers using a larger sample size is required to assess their usefulness in the diagnosis of PCOS.
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